Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?

• Eli Lilly and Viking Therapeutics some run successful the high-growth tract of obesity drugs.

• This marketplace is forecast to scope astir $100 cardinal by the extremity of the decade.

• 10 stocks we similar amended than Eli Lilly ›

Pharmaceutical elephantine Eli Lilly (NYSE: LLY) and biotech Viking Therapeutics (NASDAQ: VKTX) person 1 large happening successful common: They some enactment successful the high-growth country of value nonaccomplishment drugs. Lilly's tirzepatide, sold arsenic Mounjaro for benignant 2 diabetes and arsenic Zepbound for value loss, is bringing successful blockbuster gross and driving the company's growth. Viking's candidates, which are successful the aforesaid people of drugs arsenic Lilly's, are progressing successful late-stage objective studies.

The value nonaccomplishment cause marketplace is forecast to scope astir $100 cardinal by the extremity of the decade, and request has been consistently precocious for today's commercialized products -- truthful there's crushed to beryllium optimistic astir the maturation imaginable of these types of drugs. Considering this, which banal is much apt to beryllium a millionaire-maker -- Eli Lilly oregon Viking Therapeutics?

As mentioned, Lilly's value nonaccomplishment drugs, known arsenic dual GIP/GLP-1 receptor agonists, already are delivering blockbuster revenue. In the astir caller quarter, Mounjaro and Zepbound unneurotic brought successful much than $10 cardinal successful sales. (Though Zepbound is commercialized for value loss, doctors person besides prescribed Mounjaro for this indication.)

The institution shares marketplace enactment with Novo Nordisk, the shaper of akin drugs, Wegovy and Ozempic, and request has been truthful precocious that it surpassed the proviso of each of these products a fewer years ago. Since, the companies person ramped up accumulation to amended service demand.

Lilly's drugs are injectables, but the institution whitethorn soon participate the marketplace with an oral value nonaccomplishment drug. Regulators are reviewing the candidate, orforglipron, close now, and a imaginable support could enactment arsenic a affirmative catalyst for banal performance.

Viking is moving connected injectable and oral candidates, and they are progressive successful signifier 3 and signifier 2 trials, respectively. These drugs, similar those of Lilly, enactment connected hormones progressive successful digestion, and arsenic a result, assistance modulate humor sweetener levels and appetite. The company's trials truthful acold person met their goals and produced coagulated results, truthful there's crushed to beryllium optimistic astir Viking's aboriginal successful this field.

Though Lilly and Novo Nordisk are today's leaders successful the space, considering the levels of request for specified drugs, there's country for a caller subordinate to carve retired marketplace share. Viking and its investors whitethorn triumph large if the institution makes it to the decorativeness enactment with 1 oregon some of its candidates -- and they besides mightiness people a triumph if Viking strikes a concern oregon is acquired by a larger player. This is simply a anticipation since galore pharma and biotech companies purpose to get successful connected this lucrative market.